LIXTE Holds the World’s Only Clinical-Stage PP2A Inhibitor
Unlocking a New Era in Cancer Treatment
DENVER, Colo., Sep 09, 2025 (247marketnews.com)- LIXTE Biotechnology’s (NASDAQ:LIXT), a clinical-stage biotechnology company developing first-in-class inhibitors targeting protein phosphatases to enhance cancer treatment, lead compound, LB-100, is the world’s only clinical-stage inhibitor of protein phosphatase 2A (PP2A). This unique “off switch” mechanism positions LB-100 as a next-generation “cancer power-up” capable of transforming how traditional therapies work against solid tumors.
LB-100: A First-in-Class Molecule with Multi-Therapy Synergy
LB-100 represents a first-in-class PP2A inhibitor, with a distinctive ability to disrupt cancer’s internal repair systems and push cells into “lethal activation.” By inhibiting PP2A, LB-100 both stimulates cancer cell activity to self-destructive levels and generates neoantigens, making tumors more visible to the immune system.
Unlike traditional therapies that only kill cancer cells directly, LB-100 sensitizes tumors to immunotherapy, chemotherapy, and radiation by exposing hidden tumors and amplifying immune response.
PP2A: A Master Switch in Tumor Defense
PP2A is a key cellular enzyme regulating DNA damage repair, cell cycle progression, and survival signaling. Many cancers exploit PP2A as an “emergency off switch” to evade treatment. LB-100 disables this switch, stripping cancer cells of their defense and preventing recovery from therapy-induced stress.
This ability to break resistance barriers is particularly critical in MSS colorectal cancer (85% of cases) and ovarian clear-cell carcinoma, where current immunotherapy options are largely ineffective.
Delivering Broader Impact
One of LB-100’s most promising features is its ability to improve the impact of existing therapies at optimized doses, resulting in:
- Enhanced activity of standard treatments
- Stronger immune engagement
- A favorable combination profile
By improving both tolerability and efficacy, LB-100 has the potential to reshape treatment standards across multiple solid tumor indications.
LB-100 is currently being evaluated in Ovarian Clear-Cell Carcinoma (OCCC), in collaboration with GSK, which is providing Dostarlimab and full trial funding. This arrangement is rare and highlights the opportunity. This study is designed not only to validate LB-100’s safety and efficacy but also to demonstrate its unique role as a universal enhancer of frontline cancer therapies.
Market Opportunity & Commercial Potential
According to Fortune Business Insights, the global oncology drug market was valued at $205 billion in 2022, and is projected to reach $484 billion by 2030, growing at a CAGR of 11.4%. The immuno-oncology segment, specifically immune checkpoint inhibitors and combination therapies, represents the fastest-growing area within this market.
- Ovarian cancer represents an $8+ billion market, with clear-cell carcinoma being one of the most chemo-resistant subtypes, thus offering high value for therapies that overcome resistance.
With LB-100 showing the ability to enhance existing immunotherapies and chemotherapy agents, its positioning as an adjunctive universal enhancer that potentially opens the door to partnerships, licensing deals, and broad clinical utility across multiple multi-billion-dollar indications.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
More information can be found at: www.lixte.com
Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.
24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated by MicroCap Advisory for ongoing press and editorial coverage of LIXT. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/lixte-biotechnology/ for further 247marketnews.com LIXT disclosure information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com